Digital PCR, one of the biotechnological advancements to traditional PCR, comes across as a high-throughput absolute quantitative method making way for a reproducible and sensitive way to measure RNA or DNA in sample. Along with cancer, genetic disorders are on the rise. Digital PCR is meant to delve deep into genetic disorders as well.
At present, there is a shift to chip-based digital PCR from droplet digital PCR. This could be reasoned with aversion of cross-contamination as in chip-based digital PCR, droplets do run in channels, whereas in the former one, manual transfer of the droplets takes place. This and many such innovative practices in the background are expected to accelerate the digital PCR market in the forecast period. Persistence Market Research walks us through these findings and corrective measures to be taken in its latest market study entitled “Digital PCR Market”.
Digital PCR Market Segregation
The global digital PCR market, by product, spans consumables, instruments, and services. Application-wise, it’s basic research, clinical diagnostics, applied research, and forensic testing. By end-user, it’s pharmaceutical companies, research institutes, forensic labs, and agriculture-oriented companies. Persistence Market Research has highlighted these details with corrective modes of action in its latest market study entitled “Digital PCR Market”.
North America holds the largest market share due to growing awareness about the new-fangled diagnostic options. Plus, the fact that the number of cancer-affected patients is increasing at an exponential rate can’t be ignored. Europe stands second on this count. Research states that the year 2018 alone witnessed over 4 Mn new cancer cases all across the Europe. The Asia-Pacific is expected to grow at the fastest rate in the digital PCR market in the forecast period due to growing awareness regarding the importance of PCR and precise reading due to digitization. LATAM and MEA are in their infancy with respect to digital PCR market as of now, they are expected to pick up pace in this regard in the years to come (as there would be an increase in benevolence by then). Persistence Market Research has entailed these facts with insights in its latest market study entitled “Digital PCR Market”.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/20476
The way the Competition goes…
Persistence Market Research has profiled the key players in digital PCR market as Bio-Rad Laboratories, Inc., Agilent Technologies, Thermo Fisher Scientific Inc., Fluidigm Corp, Formulatrix, Inc., JN Medsys, and STILLA. It has also mentioned the developments on this count. For instance – QIEGEN, in January 2021, announced adding digital PCR (dPCR) platform Qiacity for mutation and wastewater testing for expanding product portfolio of the Covid-19 testing solutions.
Furthermore, in May 2020, Stilla Technologies announced that its digital PCR solution known as the “Naica System” reported to detect SARS-CoV-2 virus precisely is easily available at all the hospitals and research centers engaged in fight against Covid-19. Sround the same time, Bio-Rad Laboratories Inc. did announce that the US FDA approved its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit for EUA (Emergency Use Authorization). This test does offer higher level of accuracy and sensitivity in detecting Covid-19 infection at the initial level and does run on QXDx and QX200 ddPCR systems from Bio-Rad.
What is in Store?
The global digital PCR market is slated to grow with utmost splendor between 2021 and 2031 – Persistence Market Research